PEPTIDE CORTEXThe library
← The library

NAD+

not a peptide, but commonly discussedNot a peptide · coenzymeLongevity

Not a peptide — a dinucleotide coenzyme. Listed because it is commonly discussed alongside them.

Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
In the shop · assay ↗
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeCellular energy
MechanismCoenzyme involved in redox/mitochondrial function
EffectsCoenzyme involved in redox/mitochondrial function
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published2 sourced
Clinical trialIV pharmacokinetic pilot (Grant, 2019)
RouteIntravenous infusion
FrequencySingle infusion
Starting750 mg IV over 6 h (n=8) vs saline (n=3)
EscalationNone
TargetNot a treatment regimen. No adverse events at an infusion rate of 2 mg/min.

Summary page; primary paper not fetched. Not a peptide.

Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous; IV in clinics
FrequencySC 2-3x weekly; IV weekly to biweekly
StartingSC 50 mg, once to three times weekly (assessment phase)
EscalationIncrease by about 25 mg to 75 mg, 1-3x weekly
TargetSC 100 mg 2-3x weekly. IV 250-500 mg per session weekly or biweekly.
Cycle4-, 8- or 12-week frameworks; "No single established cycle exists"

The guide says of its own protocol: "This protocol does not relate to weight loss." Human precursor data show no weight effect.

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Quality varies; IV reactions possible; discuss with clinician

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.